Please use this identifier to cite or link to this item:
Title: Effective inhibition of xenografts of hepatocellular carcinoma (hepg2) by rapamycin and bevacizumab in an intrahepatic model
Authors: Ong, L.-C.
Song, I.-C.
Jin, Y.
Kee, I.H.C.
Siew, E.
Yu, S.
Thng, C.-H.
Huynh, H.
Chow, P.K.H. 
Keywords: 18F-FDG-PET
Hepatocellular carcinoma
Orthotopic xenograft model
Tumor vasculature
Issue Date: 2009
Source: Ong, L.-C., Song, I.-C., Jin, Y., Kee, I.H.C., Siew, E., Yu, S., Thng, C.-H., Huynh, H., Chow, P.K.H. (2009). Effective inhibition of xenografts of hepatocellular carcinoma (hepg2) by rapamycin and bevacizumab in an intrahepatic model. Molecular Imaging and Biology 11 (5) : 334-342. ScholarBank@NUS Repository.
Abstract: Purpose: Hepatocellular carcinoma (HCC) displays a characteristic hypervascularity and depends on angiogenesis for tumor growth, which thus provides a potential target for therapeutic approaches to HCC. In this study, through the use of combined micro-positron emission tomography (PET)/computed tomography (CT), we investigate if such a combined targeting of vascular endothelial growth factor (VEGF) activity and expression might retard HCC growth in an orthotopic intrahepatic xenograft model. Procedures: Xenograft models were created by intraportal vein injection of HepG2 cell suspensions in severe combined immunodeficient mice. The mice were then treated with (1) rapamycin (RAPA), a mammalian target of rapamycin pathway inhibitor; (2) bevazicumab (BEV), a VEGF monoclonal antibody; and (3) a RAPA/BEV combination. Results: Assessment of HCC progression using CT with Omnipaque and PET with 2-deoxy-2-(F-18)-fluoro-D-glucose showed that mice treated with RAPA/BEV had the lowest standardized uptake values (SUVs). At week 2, mice treated with RAPA/BEV, RAPA, and BEV all showed a marked decrease in the SUVmax readings with the greatest drop being observed in the RAPA/BEV group (1.33±0.26, 1.81±0.2, 2.05±0.4 vs. vehicle control 2.11±0.53). Conclusions: Ourresults, supported by micro-PET/CT, suggest that RAPA/BEV represents a potential novel antiangiogenic therapy for the treatment of HCC. © The Author(s) 2009.
Source Title: Molecular Imaging and Biology
ISSN: 15361632
DOI: 10.1007/s11307-009-0213-4
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Mar 8, 2018


checked on Feb 7, 2018

Page view(s)

checked on Mar 12, 2018

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.